

IMI2 Rules and Procedures

10 July 2014

Magali Poinot, Legal Manager

- I. Participation rules**
- II. Funding rules**
- III. Intellectual Property rules**
- IV. From Call to grant award**
- V. Writing a successful proposal**
- VI. More information**

A single set of rules



- Covering all H2020 research and innovation actions
- Adaptability where needed:
 - Entities eligible for funding
 - IP

Participation Rules

Attracting stakeholders

- Any entity carrying out work relevant to the IMI2 objectives in a Member State or Associated Country
- Anyone else
 - when foreseen in the annual work plan / Calls documents
 - with the agreement of the IMI JU

BUT

Not all participating entities are eligible for funding

More entities eligible for funding

- Academic institutions
- Non-profit research organisations
- Small & medium-sized enterprises (SMEs)
- *NEW* Mid-sized enterprises ($\leq 500M$)
- Non-profit patient organisations
- Non-profit public bodies and intergovernmental organisations including specialised agencies

NEW established in a Member State / associated country

- **Minimum conditions for standard collaborative actions** *NEW*

At least three legal entities, each established in a different Member State or an associated country

- **Additional conditions**

In the annual work plan (and Call documents)

Funding rules

One single funding rate per project

~~Research activities~~

~~75% of direct eligible costs~~

~~Other activities~~

~~100% of direct eligible costs~~




One project = One rate

For all beneficiaries and all activities

Defined in the annual work plan/Call documents:

- Up to 100% of the eligible costs
- but limited to a maximum of 70% for innovation projects (exception for non-profit organisations - maximum of 100%)

One single indirect cost model



A more attractive funding model

An example

 <i>Majority of beneficiaries</i>	Direct costs	Indirect costs	Total costs	% EU contribution	EU contribution
Flat-rate (20%) (or actual)	100	20	120	75%	€ 90

HORIZON 2020	Direct costs	Indirect costs	Total costs	% IMI2 contribution	IMI 2 contribution
100/25 Funding	100	25	125	100%	€ 125

Considering accounting and management principles

- **Personnel**
 - Wider acceptance of average personnel costs
 - Acceptance of supplementary payments
for non-profit organisations of up to 8000 euros / year / person
 - Less requirements for time records
- **Equipment, consumables, travels...**
- **Subcontracting**


EFPIA and Associated Partners contribution

- **EFPIA companies**
- **Other industries and partners** (when Associated Partners to IMI2)
 - ✓ In-kind (actual direct and indirect costs or average FTE) + cash contributions
 - ✓ Based on the usual management principles and accounting practices
 - ✓ Contributions from affiliated entities as part of in-kind

When relevant to IMI2 objectives: up to 30% non-EU in-kind contribution

Intellectual Property Rules

One set of rules for multiple interests



Consortium agreement

- Contractual arrangement **between all participants** to set out their rights and obligations, especially governance, liability and IPR
- Shall comply with the IMI model Grant Agreement
- Before the signature of the grant agreement with the IMI Office
- **To be adapted to the specific needs of each IMI project!**

From Call to grant award

- **Call definition**
 - Scientific Research Agenda
 - Annual Work Plan
 - Strategic Governing Groups
 - Consultation Member-Associated States/Scientific Committee
 - IMI2 approval
- **Call Launch**
- **Call Evaluation by external experts**
 - General principle: 2 stages (industry joining 2nd stage)
- **Grant Agreement, Consortium Agreement, Project implementation and reporting**

A single set of evaluation criteria

STANDARD AWARD CRITERIA

EXCELLENCE

IMPACT

QUALITY &
EFFICIENCY
OF THE ACTION

- Two stages evaluation: only “Excellence” and “Impact” considered at stage 1
- Thresholds and weighting in the Call documents
NEW Each proposal evaluated 'as it is',
not as 'what could be'

1. Excellence

The following aspects will be taken into account, to the extent that the proposed work corresponds to the topic description in the IMI2 annual work plan:

- Clarity and pertinence of the objectives
- Credibility of the proposed approach
- Soundness of the concept, including trans-disciplinary considerations, where relevant
- Extent that proposed work is ambitious, has innovation potential, and is beyond the state of the art
- Mobilisation of the necessary expertise to achieve the objectives of the topic and to ensure engagement of all relevant key stakeholders

Evaluation Criteria

2. Impact

The following aspects will be taken into account, to the extent to which the outputs of the project should contribute at the European and/or International level:

- The expected impacts of the proposed approach listed in the IMI2 annual work plan under the relevant topic
- Enhancing innovation capacity and integration of new knowledge
- Strengthening the competitiveness and industrial leadership and/or addressing specific societal challenges
- Improving European citizens' health and wellbeing and contribute to the IMI2 objectives
- Any other environmental and socially important impacts
- Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant

3. Quality and efficiency of the implementation

The following aspects will be taken into account:

- Coherence and effectiveness of the project work plan, including appropriateness of the allocation of tasks and resources
- Complementarity of the participants within the consortium (when relevant)
- Clearly defined contribution to the project plan of the industrial partners (when relevant)
- Appropriateness of the management structures and procedures, including risk and innovation management and **sustainability plan**

Keeping the momentum

A maximum Time To Grant of 8 months from the submission of the complete proposal




5 months
for informing all
applicants
on scientific evaluation



3 months
for signature of GA

NEW Legal entity validated in parallel

Simplified model Grant Agreement



Writing a successful proposal

- **Eligibility/admissibility criteria not met:**
 - submission deadline missed
 - parts of the proposal not uploaded (*this should not be a problem anymore with SOFIA/H2020 portal*)
 - submitted text does not respect the proposal template (sometimes received even slides!)
 - **proposal out of scope** (if you have doubts on how to respond to the Call, contact us)

Common Mistakes

- The proposal **does not address all the objectives** (in some cases proposals have nothing to do with the topic!)
- Applicants do not have the capabilities to address all of the objectives (e.g. redundancy between partners)
- Submitted text so concise that it **does not clearly state what is proposed** in practice
- **Ethical issues** not addressed

- **Read all the Call-relevant material that is provided on the IMI website – www.imi.europa.eu**
- Understand **IMI2 Rules** and respect them
- **If in doubt, ask** a member of the Programme Office
- Your proposal should provide **reviewers** with all the information requested to allow them to evaluate it
- Start working early (pre-materials available before)
- **Finalise your submission**

Submitting a proposal



The screenshot shows a web browser window with the URL <https://sofia.imi.europa.eu/Pages/Login.aspx> highlighted in orange. The page features the IMI logo and the text "Innovative Medicines Initiative". In the top right corner, there are links for "[Log In]", "Helpdesk", "Request Access", and "Forgot your password?". The main content area is titled "LOG IN" and contains a form with the following fields: "E-mail:" with an input box, "Password:" with an input box, and a checkbox labeled "Keep me logged in". Below the form is a "Log In" button and a link for "Forgot your password?". At the bottom of the page, there is a footer with the text "The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients." and "Specific Privacy Statement [SOFIA: Submission OF Information Application](#) Copyright © 2013 IMI.", where the link is highlighted in orange.



RESEARCH & INNOVATION

Participant Portal

European Commission > Research & Innovation > Participant Portal > Home

HOME

FUNDING OPPORTUNITIES

HOW TO PARTICIPATE

EXPERTS

SUPPORT

LOGIN

REGISTER

Welcome to the Research and Innovation Participant Portal

About the Participant Portal:

The Participant Portal is your entry point for the electronic administration of EU-funded research and innovation projects. It hosts services for managing proposals and projects throughout their lifecycle.

The Participant Portal supports activities funded mainly by the following EU programmes:

- **7th Framework Programme for Research and Technological Development (FP7)**
- **Competitiveness and Innovation Framework Programme (CIP)**

Using the Participant Portal:

As a guest user, browse the public pages to:

- search for funding opportunities
- download guidance and legal documents
- search for the participant identification code (PIC) of an organisation
- contact the FP7 support services and browse the FAQ for guidance on the Participant Portal tools

As a registered user, benefit from personalised services for proposal submission, negotiation, and project management.



WHATS NEW



FUNDING OPPORTUNITIES



HOW TO PARTICIPATE?



WORK AS AN EXPERT



ACCESS MY PERSONAL AREA



INFORMATION AND SUPPORT

More information

Reference documents

- **H2020 Rules for Participation**
- **IMI2 Delegated Regulation**
- **IMI2 Call Documents**
- **IMI2 model Grant Agreement**
- **IMI2 annotated Grant Agreement (*soon*)**

www.imi.europa.eu/content/documents

- **Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)**
Friday 11 July 2014, 14:00 – 16:00 CEST (Brussels time)
- **New procedures, rules, guidance & IPR for Calls for proposals**
Monday 14 July 2014, 14:00 – 16:00 CEST (Brussels time)
registration is now closed
Monday 3 September 2014, 14:30 – 16:00 CEST (Brussels time)
- **Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy**
Tuesday 15 July 2014, 16:00 – 18:00 CEST (Brussels time)

Crowne Plaza Hotel, Brussels, Tuesday 30 September 2014

- Workshops and presentations of topics by the topic writers
- Overview of IMI 2 funding and intellectual property (IP) rules
- Tips on applying for funding under IMI 2
- Networking opportunities
- IMI staff on hand to answer questions

We warmly encourages small and medium-sized enterprises, mid-cap businesses, patient organisations, regulatory authorities, academic teams, industry, hospitals and other organisations

Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu



Your contact points

- Contact the **IMI Programme Office**
infodesk@imi.europa.eu
- Get in touch with your **local IMI contact point**
www.imi.europa.eu/content/states-representatives-groups
- Talk to your **IMI Health National Contact Point (NCP)**

Questions and Answers